Target: NS3/4A Protease | Disease State: Hepatitis C

Introduction / Brief Description

Ganovo® (danoprevir) is a small molecule inhibitor of the hepatitis C virus NS3/4A protease invented by Array and owned by Roche. In June 2018, the China Food and Drug Administration (CFDA) approved Ganovo for the treatment of viral hepatitis C.

Clinical Trials

To learn more about danoprevir clinical trials, click here.  

Publications and Presentations



Journal of Medicinal Chemistry

Discovery of Danoprevir (ITMN-191/R7227), a Highly Selective and Potent Inhibitor of Hepatitis C Virus (HCV) NS3/4A Protease

Y. Jiang, et al.

To view all publications, click here.

These compounds and their uses are investigational and have not been approved by the U.S. Food and Drug Administration. This information is presented only for purposes of providing a general overview of our clinical trials.